Table 4.

The interaction of genetic and environmental factors for response to IFX after 1 year of treatment of CD patients.

Factor	OR (95% CI)	P value∗
Nonconcomitant use of immunomodulators	5.281 (1.360–23.09)	0.0162
Nonpenetrating	6.529 (1.651–30.41)	0.0073
G/G genotype of rs766748 in IL17F	5.123 (1.261–27.77)	0.0213
C/C or C/A genotype of rs1883136 in TRAF3IP2	10.43 (1.603–77.68)	0.0149

^∗Factors were statistically analyzed by multivariate logistic regression analysis.

IFX: infliximab; CD: Crohn's disease; OR: odds ratio; CI: confidence interval.